Electrocore stock fell 33% on Thursday after boerse-global.de reported the release of an open-label Long COVID study involving 541 participants, alongside lowered revenue forecasts and liquidity warnings.
- Open-Label Design: The trial was unblinded, meaning both participants and researchers knew who received the treatment, which can introduce bias into symptom reporting.
- Regulatory Status: The device manufacturer said that its technology lacks clearance from the U.S. Food and Drug Administration specifically for treating Long COVID.
- Preliminary Data: Out of 541 enrolled individuals, exactly 250 participants met the criteria for the final evaluation, designed strictly to generate hypotheses for future research.
Electrocore released the online publication of its randomized Long COVID study on November 12, 2026, as reported by boerse-global.de. The investigation initially enrolled 541 individuals, with 250 participants fulfilling criteria for the final evaluation. The open design aimed to supply hypotheses for subsequent investigations. Electrocore said that the findings require confirmation and that the technology remains unapproved by the US Food and Drug Administration for Long COVID.
This clinical disclosure coincided with a sharp financial downgrade. On November 4, 2026, Electrocore lowered its 2026 revenue guidance to between $39 million and $42 million, retreating from earlier projections of greater than 30% growth. During the third quarter of 2026, revenue increased by 12% compared to the prior-year period to reach $9.7 million, alongside a net loss of $1.3 million.
In its quarterly report, Electrocore disclosed that expected liquid assets would fail to cover planned operations for at least the next twelve months, raising substantial doubt regarding its ability to continue as a going concern. As of September 30, 2026, the company held approximately $7.5 million in cash, cash equivalents, and marketable securities, while presenting a preliminary 2027 revenue growth outlook of 30% to 40%.
| Metric | Previous Outlook / Q3 Data | Updated Projections / Status |
|---|---|---|
| 2026 Revenue Guidance | Growth expected over 30% | $39 million to $42 million |
| Q3 2026 Revenue | $9.7 million (12% YoY increase) | Net loss of $1.3 million |
| Cash and Equivalents | $7.5 million (as of September 30, 2026) | Insufficient for 12-month operational runway |
Individuals with implanted electrical medical devices, active local skin conditions at the stimulation site, or severe cardiovascular instabilities must exercise extreme caution. Anyone experiencing worsening neurological or systemic symptoms should immediately seek evaluation from a licensed physician.
Results must be confirmed through rigorous double-blind, placebo-controlled trials before clinical utility can be established.
- boerse-global.de – Financial and Corporate Reporting (November 12, 2026)
